Key points are not available for this paper at this time.
Our investigation confirms the biologic and prognostic significance of the tumor immune microenvironment for patients with stage I lung ADC and provides support for its use to stratify clinical outcome and immunotherapeutic interventions.
Suzuki et al. (Thu,) studied this question.